Cas no for 171500-79-1,Dalbavancin ACID Cas number search msds database,online free cas number chemistry search engine,cas number sigma aldrich

Products
Suppliers
Sourcing Requests

Post Sourcing Request Exhibition

Home
Products
Supplier
E-Trade Season
Content Hub
Industry Insights
Service & Membership
For Supplier

My Account

My Online Store

My EZSourcing

View Sourcing Requests

Customer Service
For Buyer

Search Products & Suppliers
Products Directory Suppliers Discovery Post EZSourcing
Service
Buyer Sourcing Event Contact Us
Quick links
My Favorites Recent Visit History

Home > CAS No. Inquiry > 171500-79-1

171500-79-1

[CAS Name] Dalbavancin

[Formula] C88H100Cl2N10O28

Search Products Post Sourcing Request

Basica Info

[CAS Name]Dalbavancin
[Alias]Dalbavancin;MDL 63397
[Number]171500-79-1
[EINECS]
[Formula]C88H100Cl2N10O28
[Molecular weight]1816.71

171500-79-1 Suppliers

Company

Main Products

Beijing Global Biologicals Co.Ltd

171500-79-1 lipoglycopeptide antibiotic Product Dalbavancin

Specification:

Dalbavancin (INN, trade name Zeven) is a novel second-generation lipoglycopeptide antibiotic. It belongs to the same class as vancomycin, the most widely-used and one of the few treatments available to patients infected withmethicillin-resistant Staphylococcus aureus (MRSA).

Dalbavancin (BI397) is a novel semisynthetic lipoglycopeptide that was designed to improve upon the naturalglycopeptides currently available, vancomycin and teicoplanin.

It possesses in vitro activity against a variety of Gram-positive pathogens including MRSA and MRSE. It is a once-weekly, two-dose antibiotic that Pfizer acquired when it bought Vicuron Pharmaceuticals in 2005.

Dalbavancin has undergone a phase III clinical trial for adults with complicated skin infections, but in Dec 2007 the FDA said more data was needed before approval.On September 9, 2008, Pfizer announced that it will withdraw all marketing applications in order to conduct another Phase 3 clinical trial. Durata Therapeutics acquired the rights to dalbavancin in December 2009 and has initiated two new Phase III clinical trials for treatment of acute bacterial skin and skin structure infections.Preliminary results in Dec 2012 looked good.

Send Inquiry

Beijing Global Biologicals Co.Ltd

171500-79-1 lipoglycopeptide antibiotic Product Dalbavancin

Specification:

Dalbavancin (BI397) is a novel semisynthetic lipoglycopeptide that was designed to improve upon the naturalglycopeptides currently available, vancomycin and teicoplanin.

Send Inquiry

FUJIAN COMHONY BIOTECHNOLOGY CO., LTD

Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms.

Send Inquiry

Previous page 1 2 3 4 Next page

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us: About PharmaSources; Terms of Service; Privacy Policy; Intellectual Property; Media Partners

Buy: Search Products; Post Sourcing Requests; Search Suppliers; CAS Search

Sell: Member Application; Advertising; Post Products; EZSourcing

Events: CPHI China; PMEC China; Conferences; Search Events

Help: FAQ; Contact Us; Feedback

Links：
CCCMHPIE SJGLE.com JJGLE.COM JDGLE.COM XIUGLE.COM DENGGLE.COM HPGLE.COM
Follow Us：
Pharma Sources Insight June 2024: Globalization on the Go

PharmaSources Customer Service